A Phase 2 interventional study of SPI-1005 Low dose and SPI-1005 Middle dose in Temporary Auditory Threshold Shift, sponsored by Sound Pharmaceuticals, Incorporated. Completed at 1 site in United States. Open to participants aged 18 Years to 31 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Sound Pharmaceuticals, Incorporated · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 321 studies in Hearing Loss with a site in United States — 82 open to participants now, 94 under way, 3 of them phase 3. Hearing Loss · United States.
Among the 321 studies in Hearing Loss with a site in United States, this one is the 95th largest by enrollment of the 272 interventional ones that give a count, is one of 6 that started in 2011, is one of 20 in phase 2, and was the 53rd registered.
796 studies on the registry are indexed under Hearing Loss; 194 are open to participants now.
Browse Hearing Loss studies →82 of the 321 studies in Hearing Loss with a site in United States are open now. Recruiting first, the newest first:
Sound Pharmaceuticals, Incorporated · Sites in United States
Ages 18+
Skylark Bio Inc. · Sites in United States
Ages 9 mo–7 yrs
University of Arizona · Sites in United States
Ages 18+
University of Florida · Sites in United States
Ages 25–55 · Healthy volunteers
University of Arizona · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 124 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 42 (34%) stop at 75 or younger; 46 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 31 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
321 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 31 · Phase 3 5 · Phase 4 5
First in 1997; this study’s year is marked. 6 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 83 is above the median of 44 across 561 interventional studies indexed under Hearing Loss.
Median enrollment 48 across the 272 interventional studies, 79 across the 48 observational. Of the 202 that completed or were terminated, 98 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
104 of 321 have an industry lead sponsor. The 10 most frequent:
Sound Pharmaceuticals, Incorporated is the lead sponsor of 13 studies on the registry; 2 are open to participants now.
Sound Pharmaceuticals, Incorporated has 9 studies filed under Hearing Loss — fewer than ten, so there is no comparison to draw.
34 of the studies in Hearing Loss with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06859788Phase 3Sound Pharmaceuticals, IncorporatedSPI-1005 for the Treatment of Meniere's Disease (Open Label) | 2026-12 |
| NCT05176561Gallaudet UniversityAuditory-Cognitive Training to Optimize Outcomes for Older CI Users | 2026-11 |
| NCT07913776Sonova AGPerformance of a Remote Microphone Compared to Hearing Aids Alone | 2026-11-30 |
| NCT05260307Boston University Charles River CampusImproving Spatial Perception and Speech Understanding in Multitalker Mixtures | 2026-11-30 |
| NCT06340633Sound Pharmaceuticals, IncorporatedSPI-1005 in Adults Receiving Cochlear Implant | 2026-12 |
Add all 34 to your calendar (.ics) → With an account.
Among the 321 studies in Hearing Loss with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Exposure to loud sounds can cause hearing loss. The purpose of this research study is to evaluate potential prevention of temporary changes in hearing that may occur after listening to music through an iPod or personal music player. We will measure temporary changes in hearing in subjects who listen to music and take either the study drug, SPI-1005, or a placebo for 4 days. SPI-1005 is a proprietary preparation of ebselen that allows it to be taken by mouth. Ebselen contains the mineral selenium and behaves like Glutathione Peroxidase, an enzyme that helps to rid the body of damaging chemicals caused by loud sounds.
The objective of this study was to determine the safety and efficacy of SPI-1005 in the prevention of sensorineural hearing loss or temporary auditory threshold shift (TTS) using pure tone audiometry. Subjects with normal to slight hearing loss were screened on clinic visit day 1 (CV1) and after satisfying specific otologic inclusion and exclusion criteria, were enrolled and randomized to either SPI-1000 (placebo) or one of three doses of ebselen (SPI-1005): 200, 400 or 600 mg. Subjects began taking placebo or SPI-1005 by mouth for four days beginning two days prior to CV2. On CV2 subjects had their blood drawn for peak/trough analysis of ebselen and metabolites and their baseline hearing thresholds determined by audiometry. Subjects were then exposed to 100 decibels (dBA) of sound delivered from a calibrated iPod® via insert earphones for 4 continuous hours. Subjects had their hearing serially tested at 4 additional times post-noise exposure on the same day to determine their threshold shift. Subjects returned to clinic 24 hours later on CV3 and 7 days later on CV4 for additional safety and efficacy assessments including repeat audiometry. Efficacy was determined by comparing the threshold shift in an SPI-1005 treated group vs placebo.
Exposure to SPI-1005 (ebselen and the major and minor metabolites) was quantified from plasma by LC-MS/MS. The plasma values from the peak/trough sampling were taken before and after the 5th oral dose on Clinic Visit 2 (CV2) when subjects were expected to be at steady-state. Plasma selenium levels were quantified by ICP-MS prior to dosing at CV1, at CV2 during peak/trough sampling for ebselen and metabolites, and at CV4 or 5 days after the last scheduled dose.
The multi-dose safety of SPI-1005 was determined by repeated History \& Physical examinations, serology (Chemistry Panel-20), hematology (CBC with differential), and radiology (chest x-rays). Safety was determined by comparing the changes in laboratory values in SPI-1005 groups vs placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200mg SPI-1005, capsule, bid, po, x4d
Drug: SPI-1005 Low dose
400mg SPI-1005, capsule, bid, po, x4d
Drug: SPI-1005 Middle dose
600mg SPI-1005, capsule, bid, po, x4d
Drug: SPI-1005 High dose
0mg SPI-1005, capsule, bid, po, x4d
Drug: Placebo
Oral capsules, 200 mg ebselen, twice daily, 4 days
Also known as: 200 mg Ebselen
Oral capsules, 400 mg ebselen, twice daily, 4 days
Also known as: 400 mg Ebselen
Oral capsules, 600 mg ebselen, twice daily, 4 days
Also known as: 600mgEbselen
Oral capsules, 0 mg ebselen, twice daily, 4 days
Also known as: 0 mg Ebselen
Change in Temporary Threshold Shift at 4 kHz--Intent To Treat (ITT) Population
The primary efficacy analysis was change in air conduction threshold at 4 kHz collected in the ITT Population on the day of sound exposure. Baseline hearing thresholds were collected on Clinic Visit 2 prior to sound exposure and used in calculating the primary efficacy endpoints. Hearing thresholds after sound exposure were collected and compared to baseline threshold to calculate change from baseline. Threshold changes from baseline were determined for each ear, frequency, and post sound time point, then analyzed by Mixed-effects Model Repeated Measures (MMRM) methods using triply repeated measurements for each subject. The MMRM had fixed effects for treatment, ear, frequency, and time, all 2-way interactions and the 3-way interaction treatment by-frequency-by-time plus a random effect for subject nested within treatment.
Time frame: 15 minutes post Controlled Sound Challenge
Change in Temporary Threshold Shift at 4 kHz--Per Protocol (PP) Population
The primary efficacy analysis was change in air conduction threshold at 4 kHz collected in the PP Population on the day of sound exposure. Baseline hearing thresholds were collected on Clinic Visit 2 prior to sound exposure and used in calculating the primary efficacy endpoints. Hearing thresholds after sound exposure were collected and compared to baseline threshold to calculate change from baseline. Threshold changes from baseline were determined for each ear, frequency, and post sound time point, then analyzed by Mixed-effects Model Repeated Measures (MMRM) methods using triply repeated measurements for each subject. The MMRM had fixed effects for treatment, ear, frequency, and time, all 2-way interactions and the 3-way interaction treatment by-frequency-by-time plus a random effect for subject nested within treatment.
Time frame: 15 minutes post Controlled Sound Challenge
| Milestone | SPI-1005 Low Dose | SPI-1005 Middle Dose | SPI-1005 High Dose | Placebo |
|---|---|---|---|---|
| Started | 22 | 20 | 21 | 20 |
| Completed | 20 | 20 | 21 | 19 |
| Not completed | 2 | 0 | 0 | 1 |
The primary efficacy analysis was change in air conduction threshold at 4 kHz collected in the ITT Population on the day of sound exposure. Baseline hearing thresholds were collected on Clinic Visit 2 prior to sound exposure and used in calculating the primary efficacy endpoints. Hearing thresholds after sound exposure were collected and compared to baseline threshold to calculate change from baseline. Threshold changes from baseline were determined for each ear, frequency, and post sound time point, then analyzed by Mixed-effects Model Repeated Measures (MMRM) methods using triply repeated measurements for each subject. The MMRM had fixed effects for treatment, ear, frequency, and time, all 2-way interactions and the 3-way interaction treatment by-frequency-by-time plus a random effect for subject nested within treatment.
| dbHL | SPI-1005 Low Dose | SPI-1005 Middle Dose | SPI-1005 High Dose | Placebo |
|---|---|---|---|---|
| Change in Temporary Threshold Shift at 4 kHz--Intent To Treat (ITT) Population | 3.23 (1.97 to 4.49) | 1.32 (0.06 to 2.58) | 3.81 (2.57 to 5.04) | 4.07 (2.81 to 5.34) |
The primary efficacy analysis was change in air conduction threshold at 4 kHz collected in the PP Population on the day of sound exposure. Baseline hearing thresholds were collected on Clinic Visit 2 prior to sound exposure and used in calculating the primary efficacy endpoints. Hearing thresholds after sound exposure were collected and compared to baseline threshold to calculate change from baseline. Threshold changes from baseline were determined for each ear, frequency, and post sound time point, then analyzed by Mixed-effects Model Repeated Measures (MMRM) methods using triply repeated measurements for each subject. The MMRM had fixed effects for treatment, ear, frequency, and time, all 2-way interactions and the 3-way interaction treatment by-frequency-by-time plus a random effect for subject nested within treatment.
| dB HL | SPI-1005 Low Dose | SPI-1005 Middle Dose | SPI-1005 High Dose | Placebo |
|---|---|---|---|---|
| Change in Temporary Threshold Shift at 4 kHz--Per Protocol (PP) Population | 3.35 (2.07 to 4.64) | 1.30 (0.05 to 2.55) | 3.69 (2.37 to 5.01) | 4.09 (2.84 to 5.35) |
Collected over AEs were collected over a period of roughly 1 year.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SPI-1005 Low Dose | — | 0/22 (0%) | 3/22 (13.6%) |
| SPI-1005 Middle Dose | — | 0/20 (0%) | 5/20 (25%) |
| SPI-1005 High Dose | — | 0/21 (0%) | 4/21 (19%) |
| Placebo | — | 0/20 (0%) | 2/20 (10%) |
| Event | SPI-1005 Low Dose | SPI-1005 Middle Dose | SPI-1005 High Dose | Placebo |
|---|---|---|---|---|
| CoughRespiratory, thoracic and mediastinal disorders | 0/22 | 0/20 | 2/21 | 0/20 |
| Abdominal DiscomfortGastrointestinal disorders | 0/22 | 0/20 | 1/21 | 1/20 |
| Abdominal pain upperGastrointestinal disorders | 0/22 | 1/20 | 0/21 | 0/20 |
| Procedural dizzinessInjury, poisoning and procedural complications | 1/22 | 1/20 | 0/21 | 0/20 |
| SunburnInjury, poisoning and procedural complications | 0/22 | 1/20 | 0/21 | 0/20 |
| Blood alkaline phosphatase increasedInvestigations | 0/22 | 0/20 | 1/21 | 1/20 |
| Blood phosphorus increasedInvestigations | 0/22 | 0/20 | 0/21 | 1/20 |
| HeadacheNervous system disorders | 0/22 | 1/20 | 0/21 | 0/20 |
| Rhinitis allergicRespiratory, thoracic and mediastinal disorders | 0/22 | 1/20 | 0/21 | 0/20 |
| Hot flushVascular disorders | 0/22 | 1/20 | 0/21 | 0/20 |
The study design included subjects with normal to slight hearing loss. Normal hearing is defined as having a baseline threshold of -10 dB to 15 dB at one or more tested frequencies. Slight hearing loss is defined as having baseline thresholds greater than 15 dB HL and up to 25 dB HL at one or more tested frequencies.
| Age, Customized(years) | SPI-1005 Low Dose | SPI-1005 Middle Dose | SPI-1005 High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Median | 21.0 (19 to 25) | 20.0 (19 to 23) | 20.0 (18 to 21) | 21.0 (18 to 26) | 20.0 (18 to 26) |
| Sex: Female, Male(Participants) | SPI-1005 Low Dose | SPI-1005 Middle Dose | SPI-1005 High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Female | 10 | 11 | 14 | 13 | 48 |
| Male | 12 | 9 | 7 | 7 | 35 |
| Region of Enrollment(participants) | SPI-1005 Low Dose | SPI-1005 Middle Dose | SPI-1005 High Dose | Placebo | Total |
|---|---|---|---|---|---|
| United States | 22 | 20 | 21 | 20 | 83 |
Plan to share: No
The record gives a start of Sep 2011, a primary completion of Dec 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2026, 12 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sound Pharmaceuticals, Incorporated